INmune Bio, Inc. (NASDAQ:INMB) Short Interest Update

INmune Bio, Inc. (NASDAQ:INMB) saw a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 5,510,000 shares, an increase of 9.5% from the January 15th total of 5,030,000 shares. Based on an average daily trading volume, of 330,500 shares, the days-to-cover ratio is presently 16.7 days.

Hedge Funds Weigh In On INmune Bio

Institutional investors have recently modified their holdings of the company. Barclays PLC increased its stake in INmune Bio by 601.9% during the 3rd quarter. Barclays PLC now owns 29,044 shares of the company’s stock valued at $157,000 after purchasing an additional 24,906 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of INmune Bio during the third quarter worth about $79,000. Geode Capital Management LLC increased its position in shares of INmune Bio by 6.6% during the third quarter. Geode Capital Management LLC now owns 344,466 shares of the company’s stock worth $1,857,000 after acquiring an additional 21,262 shares in the last quarter. State Street Corp raised its holdings in shares of INmune Bio by 35.1% in the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock worth $1,220,000 after acquiring an additional 58,838 shares during the last quarter. Finally, Sanctuary Advisors LLC bought a new position in INmune Bio in the 3rd quarter valued at about $113,000. 12.72% of the stock is owned by institutional investors and hedge funds.

INmune Bio Price Performance

Shares of INMB traded down $0.12 during trading hours on Monday, hitting $9.18. The stock had a trading volume of 311,175 shares, compared to its average volume of 514,959. INmune Bio has a 1-year low of $4.32 and a 1-year high of $14.49. The firm has a market capitalization of $203.52 million, a P/E ratio of -4.21 and a beta of 1.87. The firm has a 50 day simple moving average of $6.69 and a 200-day simple moving average of $6.11.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on INMB shares. Maxim Group boosted their target price on shares of INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a report on Thursday. RODMAN&RENSHAW raised INmune Bio to a “strong-buy” rating in a research note on Tuesday, January 28th. Alliance Global Partners initiated coverage on INmune Bio in a research note on Monday, October 21st. They set a “buy” rating and a $20.00 target price for the company. Scotiabank lifted their target price on INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Tuesday, February 11th. Finally, Rodman & Renshaw initiated coverage on INmune Bio in a report on Tuesday, January 28th. They set a “buy” rating and a $23.00 price target on the stock. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, INmune Bio presently has an average rating of “Buy” and a consensus price target of $22.80.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.